enGene Holdings Inc.
NASDAQ:ENGNBiotechnology
-$0.02 today
- Market cap
- $123.98M
- Beta
- -0.29
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.95
Volume 2.81M
Average 1.58M
ENGN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
enGene Holdings Inc.NASDAQ: ENGN
Research & Development · Q2 FY2026 · quarter ended Apr 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $22.2M rose 9.8% year over year, behind the +56.7% change in trailing-twelve-month research & development. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at +82.8% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +9.8% toward the trailing-twelve-month pace of +56.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 94.48M USD
- Year-over-year change
- +146.6%
- 4-year CAGR
- +65.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 94.48M | +146.6% |
| FY2024 | 2024-10-31 | 38.32M | +132.8% |
| FY2023 | 2023-10-31 | 16.46M | +6.4% |
| FY2022 | 2022-10-31 | 15.47M | +24.1% |
| FY2021 | 2021-10-31 | 12.46M | — |
Research & Development vs competitors
How ENGN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +56.7% is the 2nd highest of 10, against a peer median of +5.0%.
- Over three fiscal years its annual growth of +82.8% compares with a peer median of +15.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.31M USD | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $152.7M USD | +75.7% | +85.3% | — | |
| LTM Mar 2026 | $124.71M USD | +42.2% | +15.6% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $98.75M USD | +56.7% | +82.8% | — |
| LTM Mar 2026 | $94.68M USD | +5.0% | -1.4% | 139.0% | |
| LTM Mar 2026 | $66.77M USD | -12.8% | -2.0% | 185483.3% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | $58.79M USD | -15.8% | +15.8% | 1530.1% | |
| LTM Mar 2026 | $55.94M USD | +19.0% | +24.4% | — | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
| LTM Mar 2026 | $18.45M USD | -6.9% | -13.3% | 8.6% | |
| Peer median (excluding ENGN) | — | +5.0% | +15.7% | 1469.9% | |
Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.46M | 15.47M | 16.46M | 38.32M | 94.48M |
| Selling, General & Admin | 3.16M | 3.26M | 8.47M | 23.98M | 28.69M |
| Operating Expenses | 15.87M | 19.43M | 26.06M | 62.3M | 123.17M |
| Depreciation & Amortization | 272K | 238K | 175K | 323K | 509K |
| EBITDA | (18.15M) | (22.78M) | (94.77M) | (52.04M) | (113.8M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.87M) | (19.43M) | (26.06M) | (62.3M) | (123.17M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 25K | 129K | 1.12M | 10.41M | 9.43M |
| Interest Expense | 5.02M | 1.42M | 4.95M | 2.8M | 2.99M |
| Other Income / Expenses | (7.57M) | (5.01M) | (73.84M) | 7.14M | 5.86M |
| Income Before Tax | (23.44M) | (24.44M) | (99.9M) | (55.16M) | (117.3M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 22K | 17K | (19K) | 0 |
| Net Income | (23.44M) | (24.46M) | (99.92M) | (55.14M) | (117.3M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.01) | 0.00 | (4.24) | (1.46) | (2.29) |
| EPS (Diluted) | (0.01) | 0.00 | (4.24) | (1.46) | (2.29) |
| Weighted Avg Shares | 15.81M | 15.81M | 23.56M | 44.64M | 51.12M |
| Weighted Avg Shares (Diluted) | 15.81M | 15.81M | 23.56M | 44.64M | 51.12M |
enGene Holdings Inc.
NASDAQ:ENGN
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.